Laboratório de Biotecnologia Infecto-parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS, 96010-900, Brazil.
Laboratório de Neurobiotecnologia, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS, 96010-900, Brazil.
Parasit Vectors. 2020 Feb 11;13(1):59. doi: 10.1186/s13071-020-3923-8.
Trichomonas vaginalis is the causative agent of trichomoniasis, which is one of the most common sexually transmitted diseases worldwide. Trichomoniasis has a high incidence and prevalence and is associated with serious complications such as HIV transmission and acquisition, pelvic inflammatory disease and preterm birth. Although trichomoniasis is treated with oral metronidazole (MTZ), the number of strains resistant to this drug is increasing (2.5-9.6%), leading to treatment failure. Therefore, there is an urgent need to find alternative drugs to combat this disease.
Herein, we report the in vitro and in silico analysis of 12 furanyl N-acylhydrazone derivatives (PFUR 4, a-k) against Trichomonas vaginalis. Trichomonas vaginalis ATCC 30236 isolate was treated with seven concentrations of these compounds to determine the minimum inhibitory concentration (MIC) and 50% inhibitory concentration (IC). In addition, compounds that displayed anti-T. vaginalis activity were analyzed using thiobarbituric acid reactive substances (TBARS) assay and molecular docking. Cytotoxicity analysis was also performed in CHO-K1 cells.
The compounds PFUR 4a and 4b, at 6.25 µM, induced complete parasite death after 24 h of exposure with IC of 1.69 µM and 1.98 µM, respectively. The results showed that lipid peroxidation is not involved in parasite death. Molecular docking studies predicted strong interactions of PFUR 4a and 4b with T. vaginalis enzymes, purine nucleoside phosphorylase, and lactate dehydrogenase, while only PFUR 4b interacted in silico with thioredoxin reductase and methionine gamma-lyase. PFUR 4a and 4b led to a growth inhibition (< 20%) in CHO-K1 cells that was comparable to the drug of choice, with a promising selectivity index (> 7.4).
Our results showed that PFUR 4a and 4b are promising molecules that can be used for the development of new trichomonacidal agents for T. vaginalis.
阴道毛滴虫是滴虫病的病原体,滴虫病是全球最常见的性传播疾病之一。滴虫病发病率和患病率高,与 HIV 传播和感染、盆腔炎和早产等严重并发症相关。尽管滴虫病用口服甲硝唑(MTZ)治疗,但对这种药物的耐药菌株数量正在增加(2.5-9.6%),导致治疗失败。因此,迫切需要寻找替代药物来对抗这种疾病。
本文报告了 12 种呋喃 N-酰腙衍生物(PFUR4、a-k)对阴道毛滴虫的体外和计算机模拟分析。用七种浓度的这些化合物处理阴道毛滴虫 ATCC30236 分离株,以确定最小抑菌浓度(MIC)和 50%抑制浓度(IC)。此外,用硫代巴比妥酸反应物质(TBARS)测定和分子对接分析显示抗阴道毛滴虫活性的化合物。还在 CHO-K1 细胞中进行了细胞毒性分析。
化合物 PFUR4a 和 4b 在 6.25µM 时,暴露 24 小时后可完全杀死寄生虫,IC 分别为 1.69µM 和 1.98µM。结果表明,寄生虫死亡不涉及脂质过氧化。分子对接研究预测 PFUR4a 和 4b 与阴道毛滴虫酶、嘌呤核苷磷酸化酶和乳酸脱氢酶具有强烈的相互作用,而只有 PFUR4b 在计算机模拟中与硫氧还蛋白还原酶和甲硫氨酸 γ-裂解酶相互作用。PFUR4a 和 4b 导致 CHO-K1 细胞的生长抑制(<20%),与首选药物相当,具有有希望的选择性指数(>7.4)。
我们的研究结果表明,PFUR4a 和 4b 是有前途的分子,可用于开发治疗阴道毛滴虫的新型杀滴虫剂。